Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
End-stage renal disease (ESRD) is a state of increased arterial stiffness of extensive vessel calcifications, compared with the non-renal population. Both arterial stiffness and arterial calcifications are potent predictors of all-cause and cardiovascular mortality in ESRD patients. Several studies have documented the direct relationship between the extent and severity of arterial/coronary calcifications and outcome in dialysis patients. The relationship is strong no matter if arterial calcifications were quantified by electron-beam computed tomography or a radiological calcification score. Calcifications are early and progressive events in these patients. PWV is strongly related to the degree of sonographic determined arterial calcifications and EBCT-derived coronary artery calcium score in chronic kidney disease patients.
Calcium-based phosphate binders are associated with progressive coronary artery and aortic calcification, especially when mineral metabolism is not well controlled.
According to recent studies, sevelamer hydrochloride is a potent non-calcium-containing phosphate binder, well tolerated in ESRD. Compared with calcium-based phosphate binders, sevelamer is less likely to cause hypercalcemia, low levels of PTH, and progressive coronary and aortic calcification in hemodialysis patients. Moreover, sevelamer has a favorable effect on the lipid profile.
Less is known about the relationship between sevelamer treatment and progression of arterial stiffness. To date, there is one single study examining the influence of sevelamer (versus calcium carbonate) on the evolution of arterial stiffness in a very small number (N=15) of haemodialysis patients. These study used the same patients as historical controls, thus being methodologically rather weak. Moreover, the follow-up was quite short - 6 month.
The aim of the trial is to to quantify, in a randomized opened-labeled controlled trial the effect of sevelamer hydrochloride on the evolution of arterial stiffness parameters (pulse wave velocity and the augmentation index) in chronic haemodialysis patients and to correlate these parameters with arterial calcification assessed by a previous described radiological score of arterial calcification and echocardiographic parameters (left ventricular hypertrophy, LV dilatation, systolic and diastolic dysfunction).
| Condition | Intervention |
|---|---|
|
Haemodialyzed Patients Hyperphosphatemia |
Drug: Calcium acetate Drug: Sevelamer |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Arterial Stiffness and Arterial Calcifications Evolution in ESRD Haemodialysis Patients Treated by Sevelamer or Calcium Acetate |
- changes in arterial stiffness parameters [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- changes in calcification score [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- composite of all-cause mortality, cardiovascular mortality and major cardiovascular events [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 240 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: I
Calcium acetate 670 mg tablets
|
Drug: Calcium acetate
Calcium acetate in 240 chronic HD patients
|
|
Experimental: II
label sevelamer (RenagelR) 800 mg tablets
|
Drug: Calcium acetate
Calcium acetate in 240 chronic HD patients
Drug: Sevelamer
label sevelamer (RenagelR) 800 mg tablets
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- more than 3 months on haemodialysis
- willingness to participate
- age 18-60 yrs
- pre-dialysis blood pressure 120-160 mmHg in the last month prior to the initiation of study or recent (<1 Mo) addition of a new antihypertensive drug
- iPTH at entry 200-800 pg/mL (as per severe hyperparathyroidism)
- serum calcium at entry 2.2-2.6 mmol/L
Exclusion Criteria:
- haemodynamic instability
- uncontrolled hypertension
- any severe, debilitating disease associated with a reduced survival
- any major cardiovascular event in the last 12 month before study
- cinacalcet therapy before study entrance
- history of parathyroidectomy
- documented history of poor compliance
- serious gastrointestinal disease
Contacts and Locations| Contact: Gabriel Mircescu, Prof | +40 722214504 | gmircescu@hotmail.com |
| Contact: Ligia Petrescu, Md, PhD | +40 722296287 | ligiarares@yahoo.com |
| Romania | |
| "Dr Carol Davila" Teaching Hospital of Nephrology | Not yet recruiting |
| Bucharest, Romania, 010731 | |
| Contact: Ligia Petrescu, MD, PhD +40 722296287 ligiarares@yahoo.com | |
| Contact: Simona Hildegard Stancu, MD, PhD +40 723372069 shstancu@yahoo.com | |
| Sub-Investigator: Carmen Barbulescu, MD | |
| Sub-Investigator: Roxana Martinescu, MD | |
| Principal Investigator: Ligia Petrescu, MD, PhD | |
| Sub-Investigator: Simona Hildegard Stancu, MD, PhD | |
| "CI Parhon" Clinical Hospital | Not yet recruiting |
| Iasi, Romania | |
| Contact: Paul Gusbeth-Tatomir, MD +40 720550384 paulgusbeth@yahoo.com | |
| Contact: Nicoleta Mardare, MD | |
| Principal Investigator: Paul Gusbeth-Tatomir, MD | |
| Sub-Investigator: Nicoleta Mardare, MD | |
| Sub-Investigator: Bogdan Alexandroaie, MD | |
| Sub-Investigator: Serban Ardeleanu, MD | |
| Study Director: | Adrian Covic, Prof | "CI Parhon" Clinical Hospital, Iasi |
| Study Director: | Gabriel Mircescu, Prof | "Dr Carol Davila" Teaching Hospital of Nephrology, Bucharest, Romania |
More Information
No publications provided
| Responsible Party: | Liliana Garneata, MD. PHD, Romanian Society of Nephrology |
| ClinicalTrials.gov Identifier: | NCT00364000 History of Changes |
| Other Study ID Numbers: | 02_2006 |
| Study First Received: | August 10, 2006 |
| Last Updated: | November 12, 2011 |
| Health Authority: | Romania: National Medicines Agency |
Keywords provided by Romanian Society of Nephrology:
|
haemodialysis hyperphosphatemia sevelamer calcium acetate |
Additional relevant MeSH terms:
|
Calcinosis Hyperphosphatemia Calcium Metabolism Disorders Metabolic Diseases Phosphorus Metabolism Disorders Calcium, Dietary Sevelamer |
Calcium acetate Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Chelating Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013